Article Sidebar
Views PDF: 181
THE EFFICACY OF PLATIN–BASE CHEMOTHERAPY OF RECURRENT OR METASTATIC IN THE TRIPLE NEGATIVE BREAST CANCER
Main Article Content
Abstract
Objectives: To evaluate the efficacy of platin–base chemotherapy of metastatic of triple negative breast cancer. Patients and methods: Retrospective, descriptive study on 56 patients with recurrent or metastatic of triple negative breast cancer, were treated with platin-base chemotherapy regiment at National Cancer Hospital. Results: The mean age was 49,2 ±12,2. Mean disease-free survival time (DFS) was 16,3 months. The overall response rate (ORR) of the regimen was 58,9%. The complete response rate was 10,7%, the partial response rate was 48,2%, 12,5% of the patients were stable and 28,6% of the patients had progressive disease. ORR in first-line therapy was better than that in the second-line of treatment (ORR: 67,5% vs 37,5%; p=0,039). The median progression-free survival was 7,0 months. The common toxicity was neutropenia (63,5%), anemia (50%), 26,8% for thrombocytopenia, hair loss (46,4%), and 51,7% for vomiting and nausea. Conclusions: Platinum-based chemotherapy is effective in high response rates and progression-free survival for patients with recurrent or metastatic of triple negative breast cancer. However, it is necessary to evaluate and closely monitor the toxicity of the regimen during treatment
Article Details
Keywords
Triple negative breast cancer, platin, progression-free survival
References
2. Kaya V., Yildirim M., Yazici G. và cộng sự. (2018). Effectiveness of Platinum-Based Treatment for Triple Negative Metastatic Breast Cancer: a Meta-Analysis. Asian Pac J Cancer Prev APJCP, 19(5), 1169.
3. Brouckaert O., Wildiers H., Floris G. và cộng sự. (2012). Update on triple-negative breast cancer: prognosis and management strategies. Int J Womens Health, 4, 511–520.
4. Dent R., Trudeau M., Pritchard K.I. và cộng sự. (2007). Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res Off J Am Assoc Cancer Res, 13(15 Pt 1), 4429–4434.
5. Zhang J., Fan M., Xie J. và cộng sự. (2015). Chemotherapy of metastatic triple negative breast cancer: Experience of using platinum-based chemotherapy. Oncotarget, 6(40), 43135–43143.
6. Eisenhauer E.A., Therasse P., Bogaerts J. và cộng sự. (2009). New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer, 45(2), 228–247.
7. Chen Y., Guan Y., Wang J. và cộng sự. (2020). Platinum-based chemotherapy in advanced triple-negative breast cancer: A multicenter real-world study in China. Int J Cancer, 147(12), 3490–3499.